Table 6. comparison between standard (6 weeks) radiation therapy (Stupp et al. [1]) and hypofractionated (3 weeks) radiation therapy within multimodal approach.
| Variables | Concurrent and adjuvant TMZ CHTwith standard RT(60 Gy in 30 fractions) | Concurrent and adjuvant TMZ CHTwith hypofractionated RT(60 Gy in 15 fractions) | ||
|---|---|---|---|---|
| Extent of surgery | ||||
| Biopsy | 17% | 17.5% | ||
| Debulking | 83% | 82.5% | ||
| Radiotherapy | ||||
| Never started | 1% | 0% | ||
| Early discontinuation* | 10% | 0% | ||
| Concurrent TMZ CHT | ||||
| Never started | 2% | 4.1% | ||
| Adjuvant TMZ CHT | ||||
| Never started | 22% | 4% | ||
| Number of median cycles (range) | 3 (0-7) | 6 (0-12) | ||
| PFS | (95%CI) | (95%CI) | ||
| Median | 6.9 months | (5.8-8.2) | 10.9 months | (9.6-12.5) |
| 1year | 26.9% | (21.8-32.1) | 42.3% | (32.4-51.8) |
| 2 year | 10.7% | (7.0-14.3) | 15.2% | (8.2-24.0) |
| OS | ||||
| Median | 14.6 months | (13.2-16-8) | 15.9 months | (14.8-18.2) |
| 1 year | 61.1% | (55.4-66.7) | 72.2% | (62.1-80) |
| 2 year | 26.5% | (21.2-31.7) | 30.4% | (20.8-40.6) |
* for disease progression
TMZ=temozolomide; CHT=chemotherapy; PFS=progression free survival; OS= overall survival